The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy
Cisplatin is a platinum-based drug that is frequently used to treat multiple tumors. The anti-tumor effect of cisplatin is closely related to the tumor immune microenvironment (TIME), which includes several immune cell types, such as the tumor-associated macrophages (TAMs), cytotoxic T-lymphocytes (...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Annals of Medicine |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/07853890.2024.2447403 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841557857062879232 |
|---|---|
| author | Guandu Li Xiangyu Che Shijin Wang Dequan Liu Deqian Xie Bowen Jiang Zunwen Zheng Xu Zheng Guangzhen Wu |
| author_facet | Guandu Li Xiangyu Che Shijin Wang Dequan Liu Deqian Xie Bowen Jiang Zunwen Zheng Xu Zheng Guangzhen Wu |
| author_sort | Guandu Li |
| collection | DOAJ |
| description | Cisplatin is a platinum-based drug that is frequently used to treat multiple tumors. The anti-tumor effect of cisplatin is closely related to the tumor immune microenvironment (TIME), which includes several immune cell types, such as the tumor-associated macrophages (TAMs), cytotoxic T-lymphocytes (CTLs), dendritic cells (DCs), myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), and natural killer (NK) cells. The interaction between these immune cells can promote tumor survival and chemoresistance, and decrease the efficacy of cisplatin monotherapy. Therefore, various combination treatment strategies have been devised to enhance patient responsiveness to cisplatin therapy. Cisplatin can augment anti-tumor immune responses in combination with immune checkpoint blockers (such as PD-1/PD-L1 or CTLA4 inhibitors), lipid metabolism disruptors (like FASN inhibitors and SCD inhibitors) and nanoparticles (NPs), resulting in better outcomes. Exploring the interaction between cisplatin and the TIME will help identify potential therapeutic targets for improving the treatment outcomes in cancer patients. |
| format | Article |
| id | doaj-art-9dab427a067348d8b08ec6d32e862fbc |
| institution | Kabale University |
| issn | 0785-3890 1365-2060 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Annals of Medicine |
| spelling | doaj-art-9dab427a067348d8b08ec6d32e862fbc2025-01-06T09:45:36ZengTaylor & Francis GroupAnnals of Medicine0785-38901365-20602025-12-0157110.1080/07853890.2024.2447403The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacyGuandu Li0Xiangyu Che1Shijin Wang2Dequan Liu3Deqian Xie4Bowen Jiang5Zunwen Zheng6Xu Zheng7Guangzhen Wu8Department of Urology, the First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, ChinaDepartment of Urology, the First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, ChinaDepartment of Urology, the First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, ChinaDepartment of Urology, the First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, ChinaDepartment of Urology, the First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, ChinaDepartment of Urology, the First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, ChinaDepartment of Urology, the First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, ChinaDepartment of Cell Biology, College of Basic Medical Science, Dalian Medical University, Dalian, Liaoning, ChinaDepartment of Urology, the First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, ChinaCisplatin is a platinum-based drug that is frequently used to treat multiple tumors. The anti-tumor effect of cisplatin is closely related to the tumor immune microenvironment (TIME), which includes several immune cell types, such as the tumor-associated macrophages (TAMs), cytotoxic T-lymphocytes (CTLs), dendritic cells (DCs), myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), and natural killer (NK) cells. The interaction between these immune cells can promote tumor survival and chemoresistance, and decrease the efficacy of cisplatin monotherapy. Therefore, various combination treatment strategies have been devised to enhance patient responsiveness to cisplatin therapy. Cisplatin can augment anti-tumor immune responses in combination with immune checkpoint blockers (such as PD-1/PD-L1 or CTLA4 inhibitors), lipid metabolism disruptors (like FASN inhibitors and SCD inhibitors) and nanoparticles (NPs), resulting in better outcomes. Exploring the interaction between cisplatin and the TIME will help identify potential therapeutic targets for improving the treatment outcomes in cancer patients.https://www.tandfonline.com/doi/10.1080/07853890.2024.2447403Cisplatintumor immune microenvironmentcombination therapyimmune therapylipid metabolism disruptors |
| spellingShingle | Guandu Li Xiangyu Che Shijin Wang Dequan Liu Deqian Xie Bowen Jiang Zunwen Zheng Xu Zheng Guangzhen Wu The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy Annals of Medicine Cisplatin tumor immune microenvironment combination therapy immune therapy lipid metabolism disruptors |
| title | The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy |
| title_full | The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy |
| title_fullStr | The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy |
| title_full_unstemmed | The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy |
| title_short | The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy |
| title_sort | role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies a new approach to enhance anti tumor efficacy |
| topic | Cisplatin tumor immune microenvironment combination therapy immune therapy lipid metabolism disruptors |
| url | https://www.tandfonline.com/doi/10.1080/07853890.2024.2447403 |
| work_keys_str_mv | AT guanduli theroleofcisplatininmodulatingthetumorimmunemicroenvironmentanditscombinationtherapystrategiesanewapproachtoenhanceantitumorefficacy AT xiangyuche theroleofcisplatininmodulatingthetumorimmunemicroenvironmentanditscombinationtherapystrategiesanewapproachtoenhanceantitumorefficacy AT shijinwang theroleofcisplatininmodulatingthetumorimmunemicroenvironmentanditscombinationtherapystrategiesanewapproachtoenhanceantitumorefficacy AT dequanliu theroleofcisplatininmodulatingthetumorimmunemicroenvironmentanditscombinationtherapystrategiesanewapproachtoenhanceantitumorefficacy AT deqianxie theroleofcisplatininmodulatingthetumorimmunemicroenvironmentanditscombinationtherapystrategiesanewapproachtoenhanceantitumorefficacy AT bowenjiang theroleofcisplatininmodulatingthetumorimmunemicroenvironmentanditscombinationtherapystrategiesanewapproachtoenhanceantitumorefficacy AT zunwenzheng theroleofcisplatininmodulatingthetumorimmunemicroenvironmentanditscombinationtherapystrategiesanewapproachtoenhanceantitumorefficacy AT xuzheng theroleofcisplatininmodulatingthetumorimmunemicroenvironmentanditscombinationtherapystrategiesanewapproachtoenhanceantitumorefficacy AT guangzhenwu theroleofcisplatininmodulatingthetumorimmunemicroenvironmentanditscombinationtherapystrategiesanewapproachtoenhanceantitumorefficacy AT guanduli roleofcisplatininmodulatingthetumorimmunemicroenvironmentanditscombinationtherapystrategiesanewapproachtoenhanceantitumorefficacy AT xiangyuche roleofcisplatininmodulatingthetumorimmunemicroenvironmentanditscombinationtherapystrategiesanewapproachtoenhanceantitumorefficacy AT shijinwang roleofcisplatininmodulatingthetumorimmunemicroenvironmentanditscombinationtherapystrategiesanewapproachtoenhanceantitumorefficacy AT dequanliu roleofcisplatininmodulatingthetumorimmunemicroenvironmentanditscombinationtherapystrategiesanewapproachtoenhanceantitumorefficacy AT deqianxie roleofcisplatininmodulatingthetumorimmunemicroenvironmentanditscombinationtherapystrategiesanewapproachtoenhanceantitumorefficacy AT bowenjiang roleofcisplatininmodulatingthetumorimmunemicroenvironmentanditscombinationtherapystrategiesanewapproachtoenhanceantitumorefficacy AT zunwenzheng roleofcisplatininmodulatingthetumorimmunemicroenvironmentanditscombinationtherapystrategiesanewapproachtoenhanceantitumorefficacy AT xuzheng roleofcisplatininmodulatingthetumorimmunemicroenvironmentanditscombinationtherapystrategiesanewapproachtoenhanceantitumorefficacy AT guangzhenwu roleofcisplatininmodulatingthetumorimmunemicroenvironmentanditscombinationtherapystrategiesanewapproachtoenhanceantitumorefficacy |